<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170766</url>
  </required_header>
  <id_info>
    <org_study_id>1160.15</org_study_id>
    <nct_id>NCT02170766</nct_id>
  </id_info>
  <brief_title>Bioavailability of BIBR 953 ZW in Healthy Subjects</brief_title>
  <official_title>Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 25, 50 or 100 mg BIBR 1048 MS Film-coated Tablet With and Without Pre-treatment With Pantoprazole to Healthy Subjects. Four Groups, 2-way Crossover, Randomised, Open Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the extend of absorption of 12.5, 25, 50 and 100 mg of BIBR 1048 free base with and
      without coadministration of 40 mg pantoprazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf (Area under the concentration-time curve the time interval from 0 extrapolated to infinity) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tf (Area under the concentration-time curve over the time interval from 0 to the time of the last quantifiable concentration) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum measured concentration) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (Time from dosing to the maximum concentration) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTtot (Total mean residence time) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLtot/F (Total apparent clearance) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (Apparent volume of distribution) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal elimination rate constant) of BIBR 953 ZW</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in international normalized ratio (INR)</measure>
    <time_frame>Before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 low1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole
BIBR 1048 12.5 mg without Pantoprazole
BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 low2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole
BIBR 1048 25 mg without Pantoprazole
BIBR 1048 25 mg with 40 mg Pantoprazole (bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole
BIBR 1048 50 mg without Pantoprazole
BIBR 1048 50 mg with 40 mg Pantoprazole (bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole
BIBR 1048 100 mg without Pantoprazole
BIBR 1048 100 mg with 40 mg Pantoprazole (bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 low1</intervention_name>
    <arm_group_label>BIBR 1048 low1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 low2</intervention_name>
    <arm_group_label>BIBR 1048 low2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 medium</intervention_name>
    <arm_group_label>BIBR 1048 medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 high</intervention_name>
    <arm_group_label>BIBR 1048 high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <arm_group_label>BIBR 1048 low1</arm_group_label>
    <arm_group_label>BIBR 1048 low2</arm_group_label>
    <arm_group_label>BIBR 1048 medium</arm_group_label>
    <arm_group_label>BIBR 1048 high</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects as determined by results of screening

          -  Signed written informed consent in accordance with GCP and local legislation

          -  Age ≥ 18 and ≤ 50 years

          -  Broca ≥ - 20% and ≤ + 20%

        Exclusion Criteria:

          -  Any findings of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  History of current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  History of orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  History of

               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
                  trial as judged by the investigator

               -  Any bleeding disorder including prolonged or habitual bleeding

               -  Other hematologic disease

               -  Cerebral bleeding (e.g. after a car accident)

               -  Commotio cerebri

          -  Intake of drugs with a long half-life (&gt;24 hours) within 1 month prior to
             administration

          -  Use of any drugs which might influence the results of the trial within 10 days prior
             to administration or during trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range

          -  History of any familial bleeding disorder

          -  Thrombocytes &lt; 150000/µl
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

